Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

3 Aug 2012 17:35

For filings with the FSA include the annex For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer SILENCE THERAPEUTICSof existing shares to which voting rights are

PLCattached:ii

2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result

in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to Xqualifying financial instruments An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the

ROBERT KEITHnotification obligation:iii 4. Full name of shareholder(s) Rock ( Nominees) Limited (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or

02.08.12reached: v

6. Date on which issuer notified:

03.08.12

7. Threshold(s) that is/are crossed or

18%reached: vi, vii 8. Notified details:

A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering transaction of to the triggering shares transaction Number Number Number Number of voting % of voting rights x if possible of of of shares rights using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii GB0008433350 54,089,628 3.68% 254,089,628 254,089,628 17.33%

B: Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting rights % of voting rights financial date xvii Conversion instrument refers to xix, xx instrument period xviii Nominal Delta Spreadbet n/a n/a n/a 14,236,216 0.97% 0.97% Total (A+B+C) Number of voting rights Percentage of voting rights 268,325,844 18.30%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Proxy Voting: 10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease

to hold:

12. Date on which proxy holder will cease to hold

voting rights: 13. Additional information: 14. Contact name: ROBERT KEITH

15. Contact telephone number:

0207 491 0581

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification

obligation Full name

(including legal form of legal entities)

Contact address

(registered office for legal entities)

Phone number & email Other useful information

(at least legal representative for legal persons)

B: Identity of the notifier, if applicable

Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
20th Jan 20203:23 pmRNSHolding(s) in Company
13th Jan 20208:37 amRNSHolding(s) in Company
9th Jan 202010:04 amEQSEdison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)
9th Jan 20208:43 amRNSHolding(s) in Company
8th Jan 20209:11 amRNSHolding(s) in Company
7th Jan 202010:12 amRNSHolding(s) in Company
7th Jan 20207:00 amRNSSilence Therapeutics Announces Business Update
27th Dec 20197:00 amRNSHolding(s) in Company
17th Dec 20193:31 pmRNSManagement Change
17th Dec 20197:45 amRNSDirector disclosure
17th Dec 20197:45 amRNSBoard changes
27th Nov 20199:14 amRNSAdditional Listing
22nd Nov 20199:23 amRNSAdditional Listing
13th Nov 20192:45 pmRNSHolding(s) in Company
30th Oct 20193:13 pmRNSAdditional Listing
25th Oct 201910:25 amRNSAdditional Listing
14th Oct 201910:40 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHoldings in Company
7th Oct 20197:00 amRNSGrant of share options
4th Oct 20195:21 pmRNSDirector/PDMR Shareholding and Additional Listing
3rd Oct 20193:40 pmRNSDirector/PDMR Shareholding
2nd Oct 20195:09 pmRNSDirector/PDMR Shareholding
1st Oct 20196:06 pmRNSDirector/PDMR Shareholding and Additional Listing
30th Sep 20195:09 pmRNSDirector/PDMR Shareholding
24th Sep 20197:00 amRNSFirst research milestone for SLN500
20th Sep 20193:19 pmRNSAdditional Listing
16th Sep 20194:46 pmRNSAdditional Listing
12th Sep 20197:00 amRNSInterim results for six months ended 30 June 2019
27th Aug 20198:28 amRNSHolding(s) in Company
21st Aug 201910:14 amRNSAdditional Listing
19th Aug 20193:15 pmRNSAdditional Listing
15th Aug 20197:00 amRNSNotice of Results and R&D day
13th Aug 20197:00 amRNSAdditional Listing
8th Aug 20194:27 pmRNSAdditional Listing
7th Aug 20191:38 pmRNSAdditional Listing
6th Aug 201912:41 pmRNSAdditional Listing
5th Aug 20197:00 amRNSSilence Therapeutics appoints Jørgen Wittendorff
1st Aug 20194:22 pmRNSHolding(s) in Company
31st Jul 20198:19 amRNSHolding(s) in Company
30th Jul 20195:30 pmRNSAdditional Listing
29th Jul 20197:00 amRNSBoard Appointment
26th Jul 20191:33 pmRNSHolding(s) in Company
25th Jul 201912:26 pmRNSHolding(s) in Company
24th Jul 20198:43 amRNSHolding(s) in Company
23rd Jul 201911:27 amRNSAdditional Listing
19th Jul 20194:35 pmRNSPrice Monitoring Extension
19th Jul 20193:13 pmRNSAdditional Listing
18th Jul 201911:46 amRNSMallinckrodt to make equity investment in Silence
18th Jul 201911:45 amRNSSilence collaboration with Mallinckrodt
16th Jul 201911:46 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.